Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems (Nasdaq: DCTH) announced promising results from an independent study on its CHEMOSAT® Hepatic Delivery System for liver tumors. The study, conducted at the University Hospital of Leipzig, Germany, evaluated 33 patients with various cancers, including uveal melanoma and cholangiocarcinoma. Key findings include:

- A 91% disease control rate
- 18.2% of patients achieved complete response in the liver
- Median hepatic progression-free survival of 52 weeks across all patients
- 69 weeks median hPFS in uveal melanoma patients
- 38 weeks median hPFS in cholangiocarcinoma patients

The study highlights the efficacy and safety of repeated CHEMOSAT treatments, showing potential as an essential tool for managing primary and secondary liver tumors.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
2600 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2644Followers
    107Following
    28KVisitors
    Follow